APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Immunoglobulin for Intravenous Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Immunoglobulin for Intravenous Injection Market Outlook and Growth Opportunities 2026

Report ID 173999880431 December 2025198 pages

Choose your research edition.

Industry ResearchHuman Immunoglobulin for Intravenous Injection Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Immunoglobulin for Intravenous Injection Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Human Immunoglobulin for Intravenous Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Immunoglobulin for Intravenous Injection Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Immunoglobulin for Intravenous Injection Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Human Immunoglobulin for Intravenous Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Immunoglobulin for Intravenous Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Immunoglobulin for Intravenous Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Immunoglobulin for Intravenous Injection market include Zhenghua Shenghua, Zhongyuan Ruide, Weiguang Biological, Tiantan Biological, Taibang Biological, Yuanda shuyang, Shanghai Laishi, Kangbao Biological and Nanyue Biological, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Immunoglobulin for Intravenous Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Immunoglobulin for Intravenous Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Immunoglobulin for Intravenous Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Immunoglobulin for Intravenous Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Immunoglobulin for Intravenous Injection Segment by Company

Zhenghua Shenghua

Zhongyuan Ruide

Weiguang Biological

Tiantan Biological

Taibang Biological

Yuanda shuyang

Shanghai Laishi

Kangbao Biological

Nanyue Biological

Lvshizi

Hualan Biological

Paisi feike

Boya Biological

Human Immunoglobulin for Intravenous Injection Segment by Type

Children

Adult

Human Immunoglobulin for Intravenous Injection Segment by Application

Treatment

Diagnosis

Disease Prevention

Other

Human Immunoglobulin for Intravenous Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Immunoglobulin for Intravenous Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Immunoglobulin for Intravenous Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Immunoglobulin for Intravenous Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Human Immunoglobulin for Intravenous Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Immunoglobulin for Intravenous Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Immunoglobulin for Intravenous Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Immunoglobulin for Intravenous Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Immunoglobulin for Intravenous Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Immunoglobulin for Intravenous Injection industry.

Chapter 3: Detailed analysis of Human Immunoglobulin for Intravenous Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Immunoglobulin for Intravenous Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Immunoglobulin for Intravenous Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Immunoglobulin for Intravenous Injection Industry Trends Table 2. Human Immunoglobulin for Intravenous Injection Industry Drivers Table 3. Human Immunoglobulin for Intravenous Injection Industry Opportunities and Challenges Table 4. Human Immunoglobulin for Intravenous Injection Industry Restraints Table 5. Global Human Immunoglobulin for Intravenous Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Immunoglobulin for Intravenous Injection Revenue Share by Company (2021-2026) Table 7. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Company (2021-2026) Table 9. Global Human Immunoglobulin for Intravenous Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Immunoglobulin for Intravenous Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Immunoglobulin for Intravenous Injection Key Company Manufacturing Base & Headquarters Table 12. Global Human Immunoglobulin for Intravenous Injection Company, Product Type & Application Table 13. Global Human Immunoglobulin for Intravenous Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Immunoglobulin for Intravenous Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Children Table 18. Significant Companies of Adult Table 19. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Type (2021-2026) Table 23. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Type (2027-2032) Table 24. Global Human Immunoglobulin for Intravenous Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Immunoglobulin for Intravenous Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Immunoglobulin for Intravenous Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Type (2021-2026) Table 28. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Treatment Table 30. Significant Companies of Diagnosis Table 31. Significant Companies of Disease Prevention Table 32. Significant Companies of Other Table 33. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Application (2021-2026) Table 37. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Application (2027-2032) Table 38. Global Human Immunoglobulin for Intravenous Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Human Immunoglobulin for Intravenous Injection Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Human Immunoglobulin for Intravenous Injection Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Application (2021-2026) Table 42. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Application (2027-2032) Table 43. Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Human Immunoglobulin for Intravenous Injection Sales by Region (2021-2026) & (K Units) Table 45. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Region (2021-2026) Table 46. Global Human Immunoglobulin for Intravenous Injection Sales by Region (2027-2032) & (K Units) Table 47. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Region (2027-2032) Table 48. Global Human Immunoglobulin for Intravenous Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Human Immunoglobulin for Intravenous Injection Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Region (2021-2026) Table 51. Global Human Immunoglobulin for Intravenous Injection Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Region (2027-2032) Table 53. Global Human Immunoglobulin for Intravenous Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Human Immunoglobulin for Intravenous Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Human Immunoglobulin for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Human Immunoglobulin for Intravenous Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026) & (K Units) Table 58. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2021-2026) Table 59. Global Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032) & (K Units) Table 60. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Country (2027-2032) Table 61. Global Human Immunoglobulin for Intravenous Injection Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Human Immunoglobulin for Intravenous Injection Sales Value Market Share by Country (2021-2026) Table 63. Global Human Immunoglobulin for Intravenous Injection Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Human Immunoglobulin for Intravenous Injection Sales Value Market Share by Country (2027-2032) Table 65. Zhenghua Shenghua Company Information Table 66. Zhenghua Shenghua Business Overview Table 67. Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Product Portfolio Table 69. Zhenghua Shenghua Recent Development Table 70. Zhongyuan Ruide Company Information Table 71. Zhongyuan Ruide Business Overview Table 72. Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Product Portfolio Table 74. Zhongyuan Ruide Recent Development Table 75. Weiguang Biological Company Information Table 76. Weiguang Biological Business Overview Table 77. Weiguang Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Weiguang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 79. Weiguang Biological Recent Development Table 80. Tiantan Biological Company Information Table 81. Tiantan Biological Business Overview Table 82. Tiantan Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Tiantan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 84. Tiantan Biological Recent Development Table 85. Taibang Biological Company Information Table 86. Taibang Biological Business Overview Table 87. Taibang Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Taibang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 89. Taibang Biological Recent Development Table 90. Yuanda shuyang Company Information Table 91. Yuanda shuyang Business Overview Table 92. Yuanda shuyang Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Yuanda shuyang Human Immunoglobulin for Intravenous Injection Product Portfolio Table 94. Yuanda shuyang Recent Development Table 95. Shanghai Laishi Company Information Table 96. Shanghai Laishi Business Overview Table 97. Shanghai Laishi Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Shanghai Laishi Human Immunoglobulin for Intravenous Injection Product Portfolio Table 99. Shanghai Laishi Recent Development Table 100. Kangbao Biological Company Information Table 101. Kangbao Biological Business Overview Table 102. Kangbao Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Kangbao Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 104. Kangbao Biological Recent Development Table 105. Nanyue Biological Company Information Table 106. Nanyue Biological Business Overview Table 107. Nanyue Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Nanyue Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 109. Nanyue Biological Recent Development Table 110. Lvshizi Company Information Table 111. Lvshizi Business Overview Table 112. Lvshizi Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Lvshizi Human Immunoglobulin for Intravenous Injection Product Portfolio Table 114. Lvshizi Recent Development Table 115. Hualan Biological Company Information Table 116. Hualan Biological Business Overview Table 117. Hualan Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Hualan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 119. Hualan Biological Recent Development Table 120. Paisi feike Company Information Table 121. Paisi feike Business Overview Table 122. Paisi feike Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Paisi feike Human Immunoglobulin for Intravenous Injection Product Portfolio Table 124. Paisi feike Recent Development Table 125. Boya Biological Company Information Table 126. Boya Biological Business Overview Table 127. Boya Biological Human Immunoglobulin for Intravenous Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Boya Biological Human Immunoglobulin for Intravenous Injection Product Portfolio Table 129. Boya Biological Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Human Immunoglobulin for Intravenous Injection Distributors List Table 133. Human Immunoglobulin for Intravenous Injection Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Human Immunoglobulin for Intravenous Injection Product Image Figure 2. Global Human Immunoglobulin for Intravenous Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Immunoglobulin for Intravenous Injection Sales (2021-2032) & (K Units) Figure 5. Global Human Immunoglobulin for Intravenous Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Immunoglobulin for Intravenous Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Children Image Figure 10. Adult Image Figure 11. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Human Immunoglobulin for Intravenous Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Immunoglobulin for Intravenous Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Type (2021-2032) Figure 17. Treatment Image Figure 18. Diagnosis Image Figure 19. Disease Prevention Image Figure 20. Other Image Figure 21. Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Application (2021-2032) Figure 24. Global Human Immunoglobulin for Intravenous Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Human Immunoglobulin for Intravenous Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Application (2021-2032) Figure 27. Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Human Immunoglobulin for Intravenous Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Human Immunoglobulin for Intravenous Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 32. North America Human Immunoglobulin for Intravenous Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Human Immunoglobulin for Intravenous Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Human Immunoglobulin for Intravenous Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 38. South America Human Immunoglobulin for Intravenous Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Human Immunoglobulin for Intravenous Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Human Immunoglobulin for Intravenous Injection Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Human Immunoglobulin for Intravenous Injection Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Children
  • Adult
Applications
  • Treatment
  • Diagnosis
  • Disease Prevention
  • Other
Companies covered
  • Zhenghua Shenghua
  • Zhongyuan Ruide
  • Weiguang Biological
  • Tiantan Biological
  • Taibang Biological
  • Yuanda shuyang
  • Shanghai Laishi
  • Kangbao Biological
  • Nanyue Biological
  • Lvshizi
  • Hualan Biological
  • Paisi feike
  • Boya Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  4. 1.2.2 Global Human Immunoglobulin for Intravenous Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Human Immunoglobulin for Intravenous Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Immunoglobulin for Intravenous Injection Market Dynamics
  1. 2.1 Human Immunoglobulin for Intravenous Injection Industry Trends
  2. 2.2 Human Immunoglobulin for Intravenous Injection Industry Drivers
  3. 2.3 Human Immunoglobulin for Intravenous Injection Industry Opportunities and Challenges
  4. 2.4 Human Immunoglobulin for Intravenous Injection Industry Restraints
3 Human Immunoglobulin for Intravenous Injection Market by Company
  1. 3.1 Global Human Immunoglobulin for Intravenous Injection Company Revenue Ranking in 2025
  2. 3.2 Global Human Immunoglobulin for Intravenous Injection Revenue by Company (2021-2026)
  3. 3.3 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Immunoglobulin for Intravenous Injection Average Price by Company (2021-2026)
  5. 3.5 Global Human Immunoglobulin for Intravenous Injection Company Ranking (2024-2026)
  6. 3.6 Global Human Immunoglobulin for Intravenous Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Immunoglobulin for Intravenous Injection Company Product Type and Application
  8. 3.8 Global Human Immunoglobulin for Intravenous Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Immunoglobulin for Intravenous Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Immunoglobulin for Intravenous Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Immunoglobulin for Intravenous Injection Market by Type
  1. 4.1 Human Immunoglobulin for Intravenous Injection Type Introduction
  2. 4.1.1 Children
  3. 4.1.2 Adult
  4. 4.2 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type
  5. 4.2.1 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Immunoglobulin for Intravenous Injection Sales Value by Type
  9. 4.3.1 Global Human Immunoglobulin for Intravenous Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Immunoglobulin for Intravenous Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Type (2021-2032)
5 Human Immunoglobulin for Intravenous Injection Market by Application
  1. 5.1 Human Immunoglobulin for Intravenous Injection Application Introduction
  2. 5.1.1 Treatment
  3. 5.1.2 Diagnosis
  4. 5.1.3 Disease Prevention
  5. 5.1.4 Other
  6. 5.2 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application
  7. 5.2.1 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Human Immunoglobulin for Intravenous Injection Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Human Immunoglobulin for Intravenous Injection Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Human Immunoglobulin for Intravenous Injection Sales Value by Application
  11. 5.3.1 Global Human Immunoglobulin for Intravenous Injection Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Human Immunoglobulin for Intravenous Injection Sales Value by Application (2021-2032)
  13. 5.3.3 Global Human Immunoglobulin for Intravenous Injection Sales Value Share by Application (2021-2032)
6 Human Immunoglobulin for Intravenous Injection Regional Sales and Value Analysis
  1. 6.1 Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Immunoglobulin for Intravenous Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Human Immunoglobulin for Intravenous Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Human Immunoglobulin for Intravenous Injection Sales by Region (2027-2032)
  5. 6.3 Global Human Immunoglobulin for Intravenous Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Immunoglobulin for Intravenous Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Immunoglobulin for Intravenous Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Immunoglobulin for Intravenous Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Human Immunoglobulin for Intravenous Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  12. 6.6.2 North America Human Immunoglobulin for Intravenous Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Human Immunoglobulin for Intravenous Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Immunoglobulin for Intravenous Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  21. 6.9.2 South America Human Immunoglobulin for Intravenous Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Immunoglobulin for Intravenous Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Immunoglobulin for Intravenous Injection Sales Value Share by Country, 2025 VS 2032
7 Human Immunoglobulin for Intravenous Injection Country-level Sales and Value Analysis
  1. 7.1 Global Human Immunoglobulin for Intravenous Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Immunoglobulin for Intravenous Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Human Immunoglobulin for Intravenous Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Human Immunoglobulin for Intravenous Injection Sales by Country (2027-2032)
  6. 7.4 Global Human Immunoglobulin for Intravenous Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Immunoglobulin for Intravenous Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Immunoglobulin for Intravenous Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Immunoglobulin for Intravenous Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Immunoglobulin for Intravenous Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Immunoglobulin for Intravenous Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhenghua Shenghua
  2. 8.1.1 Zhenghua Shenghua Company Information
  3. 8.1.2 Zhenghua Shenghua Business Overview
  4. 8.1.3 Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhenghua Shenghua Human Immunoglobulin for Intravenous Injection Product Portfolio
  6. 8.1.5 Zhenghua Shenghua Recent Developments
  7. 8.2 Zhongyuan Ruide
  8. 8.2.1 Zhongyuan Ruide Company Information
  9. 8.2.2 Zhongyuan Ruide Business Overview
  10. 8.2.3 Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhongyuan Ruide Human Immunoglobulin for Intravenous Injection Product Portfolio
  12. 8.2.5 Zhongyuan Ruide Recent Developments
  13. 8.3 Weiguang Biological
  14. 8.3.1 Weiguang Biological Company Information
  15. 8.3.2 Weiguang Biological Business Overview
  16. 8.3.3 Weiguang Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Weiguang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  18. 8.3.5 Weiguang Biological Recent Developments
  19. 8.4 Tiantan Biological
  20. 8.4.1 Tiantan Biological Company Information
  21. 8.4.2 Tiantan Biological Business Overview
  22. 8.4.3 Tiantan Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tiantan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  24. 8.4.5 Tiantan Biological Recent Developments
  25. 8.5 Taibang Biological
  26. 8.5.1 Taibang Biological Company Information
  27. 8.5.2 Taibang Biological Business Overview
  28. 8.5.3 Taibang Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Taibang Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  30. 8.5.5 Taibang Biological Recent Developments
  31. 8.6 Yuanda shuyang
  32. 8.6.1 Yuanda shuyang Company Information
  33. 8.6.2 Yuanda shuyang Business Overview
  34. 8.6.3 Yuanda shuyang Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Yuanda shuyang Human Immunoglobulin for Intravenous Injection Product Portfolio
  36. 8.6.5 Yuanda shuyang Recent Developments
  37. 8.7 Shanghai Laishi
  38. 8.7.1 Shanghai Laishi Company Information
  39. 8.7.2 Shanghai Laishi Business Overview
  40. 8.7.3 Shanghai Laishi Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shanghai Laishi Human Immunoglobulin for Intravenous Injection Product Portfolio
  42. 8.7.5 Shanghai Laishi Recent Developments
  43. 8.8 Kangbao Biological
  44. 8.8.1 Kangbao Biological Company Information
  45. 8.8.2 Kangbao Biological Business Overview
  46. 8.8.3 Kangbao Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kangbao Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  48. 8.8.5 Kangbao Biological Recent Developments
  49. 8.9 Nanyue Biological
  50. 8.9.1 Nanyue Biological Company Information
  51. 8.9.2 Nanyue Biological Business Overview
  52. 8.9.3 Nanyue Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Nanyue Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  54. 8.9.5 Nanyue Biological Recent Developments
  55. 8.10 Lvshizi
  56. 8.10.1 Lvshizi Company Information
  57. 8.10.2 Lvshizi Business Overview
  58. 8.10.3 Lvshizi Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lvshizi Human Immunoglobulin for Intravenous Injection Product Portfolio
  60. 8.10.5 Lvshizi Recent Developments
  61. 8.11 Hualan Biological
  62. 8.11.1 Hualan Biological Company Information
  63. 8.11.2 Hualan Biological Business Overview
  64. 8.11.3 Hualan Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hualan Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  66. 8.11.5 Hualan Biological Recent Developments
  67. 8.12 Paisi feike
  68. 8.12.1 Paisi feike Company Information
  69. 8.12.2 Paisi feike Business Overview
  70. 8.12.3 Paisi feike Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Paisi feike Human Immunoglobulin for Intravenous Injection Product Portfolio
  72. 8.12.5 Paisi feike Recent Developments
  73. 8.13 Boya Biological
  74. 8.13.1 Boya Biological Company Information
  75. 8.13.2 Boya Biological Business Overview
  76. 8.13.3 Boya Biological Human Immunoglobulin for Intravenous Injection Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Boya Biological Human Immunoglobulin for Intravenous Injection Product Portfolio
  78. 8.13.5 Boya Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Immunoglobulin for Intravenous Injection Value Chain Analysis
  2. 9.1.1 Human Immunoglobulin for Intravenous Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Immunoglobulin for Intravenous Injection Sales Mode & Process
  6. 9.2 Human Immunoglobulin for Intravenous Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Immunoglobulin for Intravenous Injection Distributors
  9. 9.2.3 Human Immunoglobulin for Intravenous Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst